explore -WSS

explore

author：focus 2025-10-02 09:55:27 - browse：536

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Cherokee Nation medical school graduates its first class

hotspot

WSS

HHS suspends federal funding for EcoHealth Alliance

CVS is willing to dump 10% of its Medicare Advantage members

STAT reporters are Pulitzer Prize finalists for investigative reporting

As H5N1 spreads in cows, experts warn against drinking raw milk

WuXi Biologics execs register to lobby as Congress comes for the company

Galapagos to make CAR

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Drug repurposing or repositioning? The language matters

Health tech investors get more selective as pandemic boom fades

Virginia high school admissions case could be legal follow

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Malaria cases in Florida and Texas: Here’s what you need to know

Fertility clinic egg and embryo storage is a disaster

Medicare details structure of new drug price negotiation program

Ripples from Flovent's discontinuation is killing children with asthma

How to save PrEP access — and even expand it

Smaller biotechs seek to piggyback on weight loss drug boom

focus

STAT Summit: How researchers deal with rejection

STAT series 'Denied by AI' wins major journalism prizes

Fertility clinic egg and embryo storage is a disaster

J&J lung cancer data amount to new salvo against AstraZeneca

Lilly’s weekly insulin works as well as daily products, new studies show

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

hotspot

leisure time

Wikipedia

Wikipedia